Insider Selling: Twist Bioscience (NASDAQ:TWST) Insider Sells 324 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 324 shares of the stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $34.56, for a total value of $11,197.44. Following the transaction, the insider owned 144,680 shares of the company’s stock, valued at approximately $5,000,140.80. This trade represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Dennis Cho also recently made the following trade(s):

• On Monday, November 3rd, Dennis Cho sold 1,019 shares of Twist Bioscience stock. The stock was sold at an average price of $32.08, for a total transaction of $32,689.52.
• On Thursday, October 30th, Dennis Cho sold 6,515 shares of Twist Bioscience stock. The stock was sold at an average price of $31.44, for a total transaction of $204,831.60.
• On Monday, October 6th, Dennis Cho sold 3,876 shares of Twist Bioscience stock. The shares were sold at an average price of $32.19, for a total value of $124,768.44.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST traded down $1.22 during trading on Tuesday, reaching $33.84. The stock had a trading volume of 804,463 shares, compared to its average volume of 1,350,107. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.33 and a current ratio of 3.64. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $55.33. The firm’s 50 day moving average price is $31.02 and its two-hundred day moving average price is $31.19. The stock has a market cap of $2.07 billion, a PE ratio of -25.83 and a beta of 2.24.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.05). Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. The business had revenue of $99.01 million during the quarter, compared to analyst estimates of $97.40 million. On average, research analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Barclays boosted their price objective on Twist Bioscience from $37.00 to $39.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Stephens assumed coverage on shares of Twist Bioscience in a research report on Monday, November 3rd. They set an “overweight” rating and a $41.00 price objective for the company. Evercore ISI cut their target price on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday. Eight research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $44.88.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors have recently modified their holdings of the stock. Quarry LP purchased a new stake in shares of Twist Bioscience during the third quarter worth $28,000. Smartleaf Asset Management LLC grew its stake in Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after purchasing an additional 442 shares in the last quarter. National Bank of Canada FI acquired a new position in Twist Bioscience in the 3rd quarter worth about $46,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Twist Bioscience by 15.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock worth $85,000 after purchasing an additional 302 shares in the last quarter. Finally, Geneos Wealth Management Inc. acquired a new stake in shares of Twist Bioscience during the 2nd quarter valued at about $97,000.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.